Healthcare Services

Upadacitinib Market Expected to Reach $2.89 Billion by 2030

April 28, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Upadacitinib Market During 2026–2030?

The upadacitinib market has experienced significant expansion in recent years. It is projected to grow from $1.5 billion in 2025 to $1.71 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.1%. This historical growth can be attributed to factors such as the increasing prevalence of rheumatoid arthritis, the limitations observed in conventional DMARDs, a growing demand for targeted therapies, the availability of oral treatment options, and the expansion of specialty care services.

The upadacitinib market is projected for swift expansion in the coming years, reaching $2.89 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.0%. This anticipated growth during the forecast period is fueled by factors such as a rise in clinical approvals for novel indications, a heightened emphasis on personalized autoimmune treatments, the broadening of oral immunotherapy pipelines, increased investments in inflammatory disease research, and the greater uptake of advanced small molecule drugs. Key trends expected over this period involve a surge in the adoption of JAK inhibitor therapies, an escalating preference for oral targeted treatments, the expanding utilization of small molecule immunomodulators, a wider array of autoimmune disease indications, and an intensified focus on managing diseases over the long term.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21311&type=smp

What Factors Are Contributing To The Growth Of The Upadacitinib Market?

The growing occurrence of autoimmune diseases is anticipated to boost the upadacitinib market’s expansion moving forward. Autoimmune diseases are conditions where the immune system mistakenly attacks the body’s healthy cells, perceiving them as foreign invaders. The prevalence of these diseases is influenced by genetic predisposition, environmental catalysts, and alterations in lifestyle and immune system behavior. Upadacitinib aids in autoimmune conditions by specifically targeting and inhibiting JAK1, which effectively reduces inflammation and modulates the immune response in ailments such as rheumatoid arthritis and psoriatic arthritis. For instance, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA) in 2025. These numbers are expected to increase by 2040 to approximately 280,040 males and 479,828 females. Therefore, the escalating incidence of autoimmune diseases is stimulating the growth of the upadacitinib market.

What Segment Categories Shape The Upadacitinib Market Segment Landscape?

The upadacitinib market covered in this report is segmented –

1) By Drug Classes: Janus Kinase Inhibitors, Antirheumatic Agents, Small Molecule Drugs

2) By Application: Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s Disease

3) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Janus Kinase Inhibitors: JAK1 Inhibitors, JAK2 Inhibitors, JAK3 Inhibitors, TYK2 Inhibitors

2) By Antirheumatic Agents: Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic DMARDs, Conventional Synthetic DMARDs

3) By Small Molecule Drugs: Oral Small Molecule Drugs, Topical Small Molecule Drugs

What Trends Are Shaping The Future Of The Upadacitinib Market?

Companies operating in the upadacitinib market are focusing on developing innovative products like oral Janus kinase (JAK) inhibitors to broaden treatment options for autoimmune diseases. Oral Janus kinase inhibitors are small-molecule medications that block Janus kinase enzymes, suppressing immune overactivation and inflammation to effectively treat autoimmune and inflammatory conditions. For instance, in April 2023, AbbVie Inc., a US-based pharmaceutical company, announced that RINVOQ (upadacitinib) received European Commission approval for treating moderately to severely active Crohn’s disease. This oral formulation permits once-daily administration, improving both convenience and adherence for patients. The oral delivery method also provides a quicker onset of action compared to traditional treatments, making it simpler for patients to follow their prescribed plans.

Who Are The Companies Operating Across The Upadacitinib Market Value Chain?

Major companies operating in the upadacitinib market are AbbVie Inc, Pfizer Inc, Eli Lilly and Company, Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi SA, Takeda Pharmaceutical Company Ltd, Astellas Pharma Inc, AstraZeneca PLC, Gilead Sciences Inc, Teva Pharmaceutical Industries Ltd, Mitsubishi Tanabe Pharma Corporation, Kyowa Hakko Kirin Co Ltd, Galapagos NV, UCB SA, Daiichi Sankyo Company Ltd, Horizon Therapeutics plc, Regeneron Pharmaceuticals Inc.

Get The Full Upadacitinib Market Report:

https://www.thebusinessresearchcompany.com/report/upadacitinib-global-market-report

Which Region Leads The Upadacitinib Market In Overall Market Size?

North America was the largest region in the upadacitinib market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the upadacitinib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Upadacitinib Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/upadacitinib-global-market-report

Browse Through More Reports Similar to the Global Upadacitinib Market 2026, By The Business Research Company

Denosumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Macadamia Market Report

https://www.thebusinessresearchcompany.com/report/macadamia-global-market-report

Capecitabine Market Report

https://www.thebusinessresearchcompany.com/report/capecitabine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795